Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Humalog Mix 50 is a premixed insulin formulation containing 50% insulin lispro protamine suspension (intermediate-acting) and 50% insulin lispro injection (rapid-acting). It is indicated for the treatment of diabetes mellitus in adults and children requiring insulin therapy for glycemic control. The rapid-acting component helps control postprandial glucose spikes, while the protamine-bound intermediate-acting component provides basal insulin coverage. Humalog Mix 50 offers a convenient alternative to separate basal and bolus insulin regimens in patients with consistent meal patterns.
Fact Table | |
Formula | C257H383N65O77S6 (insulin lispro) |
License | US FDA; EMA |
Bioavailability | ~55–77% (subcutaneous) |
Legal status | Prescription only |
Chemical Name | Insulin lispro and insulin lispro protamine |
Elimination half-life | Insulin lispro: ~1 hour; Protaminated form: ~5–6 hours |
Dosage (Strength) | 100 units/mL; 3 mL cartridges, vials, or KwikPen |
Pregnancy | Category B – considered safe with monitoring |
Brands | Humalog Mix50, Humalog Mix50 KwikPen (by Eli Lilly) |
Protein binding | Negligible |
PubChem CID | 16129678 (insulin lispro) |
MedlinePlus | a699001 |
ChEBI | CHEBI:80695 |
ATC code | A10AD05 |
DrugBank | DB01306 |
KEGG | D04588 |
Routes of administration | Subcutaneous injection |
Humalog Mix 50 is administered subcutaneously, typically within 15 minutes before a meal.
Dosing is individualized based on blood glucose monitoring, metabolic needs, and clinician guidance.
It may be used once or twice daily, depending on meal timing and glycemic goals.
Rotate injection sites regularly (abdomen, thigh, upper arm) to prevent lipodystrophy.
Do not administer intravenously or use in insulin pumps. Do not mix with other insulins.
Each mL of Humalog Mix 50 contains:
Insulin lispro protamine suspension 50% (intermediate-acting)
Insulin lispro 50% (rapid-acting)
Other ingredients include:
Glycerin, protamine sulfate, zinc oxide, phenol, m-cresol, and water for injection
Available in:
Vials (10 mL)
KwikPen prefilled pen (3 mL)
Concentration: 100 units/mL (U-100)
Humalog Mix 50 is contraindicated in:
Patients with hypersensitivity to insulin lispro or any component of the formulation
Patients experiencing hypoglycemia at the time of administration
Careful monitoring is required during insulin initiation or dosage adjustment. Dose changes may be necessary with changes in physical activity, diet, or renal/hepatic function. Hypoglycemia is the most common and serious adverse effect. Do not share pens or syringes to prevent cross-contamination. Avoid use in patients with unstable or rapidly fluctuating glucose levels, as premixed insulin may not allow for fine-tuned control.
Common and potential side effects include:
Hypoglycemia
Injection site reactions (e.g., redness, swelling, itching)
Lipodystrophy with repeated use at the same site
Weight gain
Edema
Rare: allergic reactions, insulin resistance, or anaphylaxis